2024 EACTS guidelines on perioperative medication in adult cardiac surgery: embracing precision medicine driven by strong evidence-based methodology
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Guidelines are pivotal for optimal patient management and should be grounded by evidence-based medicine with accurate methodology.1 The European Association of Cardio-Thoracic Surgery has recently released the “2024 EACTS Guidelines on Perioperative Medication in Adult Cardiac Surgery”,2 which address significant novel advancements in the pharmacological management of adult patients undergoing various types of cardiac surgery, including open-heart surgery (coronary and non-coronary) and transcatheter aortic valve implantation. These guidelines comprise several drug classes and provide recommendations on their use, discontinuation and/or (re)introduction at the different phases surrounding elective, urgent or emergent cardiac interventions: early before, during, and after the operation, both short- and long-term. A substantial portion of the document focuses on antithrombotic agents, and several novel aspects and approaches warrant attention....
Altmetrics
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Most read articles by the same author(s)
- Anna Falanga, Hugo Ten Cate, Bianca Rocca, How to manage antithrombotic treatments in thrombocytopenic patients with cancer. Comments on the European Haematology Association guidelines , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
